Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically confirmed chronic hepatitis~2. Age ≥18 years~3. Subject able to provide written informed consent~4. Stable disease for 24 months~5. Currently being administered prednisone (with or without azathioprine) therapy at the lower stable dose to maintain remission or Budesonide (with or without azathioprine) therapy at the lower stable dose to maintain remission or azathioprine alone.~6. ALT ≤ 30 U/L in men and ≤19 U/L in women~7. IgG \< 1450 mg/dL~8. Non-pregnant women (via negative pregnancy test) and women with no intention to become pregnant during the term of the trial or three months after cessation of CBD treatment~Exclusion Criteria:~1. Viral Hepatitis (HAV, HBV, HCV)~2. HIV~3. Serious psychiatric or psychological disorders~4. Active consumption of illicit drugs including cannabis or derivatives (at least 1 month before study start)~5. Overlap disease with Primary Biliary Cholangitis or Primary Sclerosing Cholangitis~6. IgG4 related Autoimmune Hepatitis~7. Transplant patients~8. Patients with significant cardiac, respiratory or active malignance disease comorbidities.~9. Renal comorbidity: eGFR \< 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2)~10. Cirrhosis~11. Patients treated with corticoids for other indication except Autoimmune Hepatitis~12. Patient that are taking immunomodulatory medications for other indication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sintetic Cannabidiol (Type: EXPERIMENTAL): Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).